Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis : An observational study
OBJECTIVES: Methotrexate (MTX) is the most commonly used cost-effective disease-modifying antirheumatoid drug (DMARD). Its main dose-limiting adverse effects are hepatic and hematopoietic. This cross-sectional, observational study evaluated the prevalence of hepatic and hematological adverse effects with long-term low-dose MTX therapy.
MATERIALS AND METHODS: Rheumatoid arthritis (RA) patients taking ≤15 mg/week MTX for at least 2 years were enrolled from the rheumatology outpatient department. Demographic, disease, drug treatment profiles, and hematological and hepatic enzyme levels were noted.
RESULTS: Of the 204 patients enrolled, the frequency of raised alanine transaminase level (≥3-fold rise above the upper limit of normal) was 6.37% (95% confidence interval of 3.76-10.59) including two biopsy-proven hepatic fibrosis cases. About 5.4% had severe anemia (<8 g/dl) and 4.4% had leukopenia.
CONCLUSION: Long-term low-dose MTX is safe in RA patients in the Indian population. The patterns of adverse effects were similar to those documented in earlier studies. However, our study results suggest that disease duration, cumulative MTX dose, concomitant DMARD intake are not risk factors associated with hepatic or hematological adverse effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Indian journal of pharmacology - 48(2016), 5 vom: 01. Sept., Seite 591-594 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dubey, Lily [VerfasserIn] |
|---|
| Themen: |
Adverse effects |
|---|
| Anmerkungen: |
Date Completed 30.06.2017 Date Revised 08.04.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM265149339 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM265149339 | ||
| 003 | DE-627 | ||
| 005 | 20231224211641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0883.xml |
| 035 | |a (DE-627)NLM265149339 | ||
| 035 | |a (NLM)27721549 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dubey, Lily |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis |b An observational study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2017 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Methotrexate (MTX) is the most commonly used cost-effective disease-modifying antirheumatoid drug (DMARD). Its main dose-limiting adverse effects are hepatic and hematopoietic. This cross-sectional, observational study evaluated the prevalence of hepatic and hematological adverse effects with long-term low-dose MTX therapy | ||
| 520 | |a MATERIALS AND METHODS: Rheumatoid arthritis (RA) patients taking ≤15 mg/week MTX for at least 2 years were enrolled from the rheumatology outpatient department. Demographic, disease, drug treatment profiles, and hematological and hepatic enzyme levels were noted | ||
| 520 | |a RESULTS: Of the 204 patients enrolled, the frequency of raised alanine transaminase level (≥3-fold rise above the upper limit of normal) was 6.37% (95% confidence interval of 3.76-10.59) including two biopsy-proven hepatic fibrosis cases. About 5.4% had severe anemia (<8 g/dl) and 4.4% had leukopenia | ||
| 520 | |a CONCLUSION: Long-term low-dose MTX is safe in RA patients in the Indian population. The patterns of adverse effects were similar to those documented in earlier studies. However, our study results suggest that disease duration, cumulative MTX dose, concomitant DMARD intake are not risk factors associated with hepatic or hematological adverse effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Adverse effects | |
| 650 | 4 | |a hematological | |
| 650 | 4 | |a hepatotoxicity | |
| 650 | 4 | |a methotrexate | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Alanine Transaminase |2 NLM | |
| 650 | 7 | |a EC 2.6.1.2 |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Chatterjee, Suparna |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Alakendu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of pharmacology |d 1982 |g 48(2016), 5 vom: 01. Sept., Seite 591-594 |w (DE-627)NLM078779812 |x 1998-3751 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2016 |g number:5 |g day:01 |g month:09 |g pages:591-594 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2016 |e 5 |b 01 |c 09 |h 591-594 | ||